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CP110, a Cell Cycle-Dependent CDK Substrate,
Regulates Centrosome Duplication in Human Cells
dynamics will be required to elucidate the mechanisms
underlying tumorigenesis in humans.
It is clear that links must exist between the cell cycle
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and Brian David Dynlacht1,3
1Department of Molecular and Cellular Biology and the centrosome cycle—the process of duplicating
and separating centrosomes—because this organelle,Harvard University
16 Divinity Avenue like the genome, is duplicated only once per cycle (re-
viewed in Hinchcliffe and Sluder, 2001). In addition, keyCambridge, Massachusetts 02138
2 Center for Cancer Research events in the centrosome cycle occur at temporally de-
fined stages of the cell cycle. Thus, centrosome duplica-Massachusetts Institute of Technology
Cambridge, Massachusetts 02139 tion is initiated in mammalian cells during late G1 phase
as daughter centrioles begin to grow semiconservatively
from their parents. During S and G2 phases, centrioles
continue to elongate, and during this time, centrosomesSummary
are situated near the nucleus and lie in proximity to one
another. However, as cells enter prophase, the centro-Centrosome duplication and separation are linked in-
somes begin to separate, migrating to opposite polesextricably to certain cell cycle events, in particular
and establishing the mitotic spindle.activation of cyclin-dependent kinases (CDKs). How-
Recent experiments have suggested how the two keyever, relatively few CDK targets driving these events
events in the centrosome cycle, duplication and separa-have been uncovered. Here, we have performed a
tion, are linked to the cell cycle and more specificallyscreen for CDK substrates and have isolated a target,
to the activation of CDKs, pivotal enzymes that driveCP110, which is phosphorylated by CDKs in vitro and
eukaryotic cell cycle progression. Two distinct cyclin/in vivo. Human CP110 localizes to centrosomes. Its
CDK complexes have been implicated in the regulationexpression is strongly induced at the G1-to-S phase
of centrosome duplication. Cyclin E/CDK2 activity playstransition, coincident with the initiation of centrosome
a central role in driving the embryonic frog and mamma-duplication. RNAi-mediated depletion of CP110 indi-
lian cell cycle through the G1-to-S transition and intocates that this protein plays an essential role in centro-
the DNA replicative phase, and its activation coincidessome duplication. Long-term disruption of CP110
with centrosome duplication. In Xenopus embryos,phosphorylation leads to unscheduled centrosome
cyclin E/CDK2 appears to play a critical role in the cen-separation and overt polyploidy. Our data suggest that
trosome cycle, as inhibition of this kinase prevents cen-CP110 is a physiological centrosomal CDK target that
triole separation, a requisite event prior to duplicationpromotes centrosome duplication, and its deregula-
(Hinchcliffe et al., 1999; Lacey et al., 1999). A role for thistion may contribute to genomic instability.
enzyme has also been revealed in somatic mammalian
cells, as recent studies have identified two cyclin
Introduction E/CDK2 substrates, nucleophosmin/B23 and Mps1/
TTK, which localize to the centrosome and regulate its
Although centrosomes were first described cytologically duplication (Fisk and Winey, 2001; Okuda et al., 2000).
over 100 years ago, many questions remain regarding A second CDK complex, cyclin A/CDK2, may be involved
the dynamic changes in structure and function of this in centrosome duplication in somatic mammalian cells,
organelle. The centrosome is comprised of two perpen- because in some settings this enzyme, but not cyclin
dicularly oriented centrioles surrounded by pericentrio- E/CDK2, was able to drive duplication of the organelle
lar material, a poorly defined matrix from which microtu- (Meraldi et al., 1999). It therefore appears that both en-
bules emanate and elongate. Correct chromosomal zymes participate in centrosome duplication events, but
segregation depends absolutely on the establishment further work will be required to understand the relative
of a bipolar mitotic spindle. Many human tumors and contributions of each.
cells that have lost certain tumor suppressor genes dis- Despite the knowledge that CDKs play a role in regu-
play centrosome amplification, leading to defects in lating the centrosome cycle and the recent identification
chromosome segregation and aneuploidy (Fukasawa et of two substrates, relatively little is known about how
al., 1996; Pihan et al., 1998; Xu et al., 1999). Further, these substrates control duplication and separation,
several centrosomal defects have been noted in human how their activities are periodically modified by CDKs,
tumors in addition to increases in centrosome number, and how the loss of normal regulation contributes to
including an accumulation of pericentriolar material, su- errors in chromosome segregation, ploidy, and cancer.
pernumerary centrioles, and increased numbers of mi- In this report, we describe the isolation of an uncharac-
crotubule organizing centers that nucleate abnormally terized human protein, CP110, which is phosphorylated
large arrays of microtubules (Lingle et al., 1998). Given in vitro and in vivo by CDKs that function during S phase
that genomic instability is a hallmark of cancer cells, a and in subsequent phases of the cell cycle. The abun-
detailed understanding of all aspects of centrosome dance of CP110 is regulated during the cell cycle, peak-
ing during S phase and diminishing thereafter. CP110
is an integral centrosomal component, colocalizing with3 Correspondence: dynlacht@biosun.harvard.edu
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a known centriolar protein. Downregulation of endoge- stable complexes with this recombinant protein in vitro,
reminiscent of other proteins bearing the RXL motif (Fig-nous CP110 with small interfering RNAs (siRNAs) had a
marked effect on centrosome duplication. Expression ure 2B). We localized the majority (nine of ten) of poten-
tial CDK2 phosphorylation sites in CP110 to an amino-of a mutant derivative of CP110 refractory to CDK phos-
phorylation provokes marked polyploidy. Thus, we have terminal fragment (GST-N1; Figure 1B) and performed
site-directed mutagenesis to eliminate each putativeisolated an important centrosomal CDK substrate that
participates in the control of centrosome duplication phosphorylation site combinatorially. A mutant (GST-
mut) lacking eight potential sites was completely refrac-and regulation or maintenance of ploidy.
tory to phosphorylation (Figure 2A). Interestingly, elimi-
nation of the carboxy-terminal RXL motif (GST-N2) nul-Results
lified phosphorylation by cyclin E/CDK2 but not the other
kinases.Isolation of CP110, a CDK Substrate
We compared the sites phosphorylated by cyclinIn an effort to isolate targets of CDKs associated with
E/CDK2 in vitro with those modified in vivo by two-the centrosome, we used a previously established pro-
dimensional phosphopeptide analysis. We transfectedcedure to screen a human cDNA expression library with
mammalian cells with a plasmid encoding epitope-a recombinant, dominant-negative form of cyclin
tagged CP110, and after metabolic labeling, immuno-E/CDK2 which had been radiolabeled by prior incuba-
precipitated lysates with anti-epitope antibodies. CP110tion with the wild-type version of this kinase (Zhao et
was robustly phosphorylated in vivo by an endogenousal., 1998). We reasoned that such a protocol might also
kinase(s), and after tryptic digestion the pattern of re-allow for the isolation of cyclin A/CDK2 substrates as
sulting phosphopeptides substantially overlapped withwell as substrates of the mitotic kinases, because in
those observed after phosphorylation of CP110 in vitromany cases CDKs display overlapping specificity. We
with recombinant cyclin E/CDK2 as well as cyclinscreened a total of 2  105 plaques from which we
A/CDK2 and cyclin B/CDC2 (data not shown). Theseisolated six positive clones, including two cDNAs encod-
data suggest that CP110 is an authentic in vivo substrateing previously characterized proteins, p21WAF1/Cip1/CAP20
for cyclin/CDK complexes that function from S throughand proliferating cell nuclear antigen (PCNA; Figure 1A).
M phase.Both proteins have been shown to interact with cyclin/
Prior to more extensive analysis, we determined thatCDK complexes (Harper et al., 1993; Koundrioukoff et
our CP110 clone represents a full-length cDNA. First,al., 2000; Xiong et al., 1993), confirming the success of
there is an in-frame termination codon upstream of theour screen. In addition, we identified four uncharacter-
first ATG present in this cDNA. Second, Northern blotized cDNAs, one of which was further characterized
analysis (Figure 3A) revealed a single message of 5.6(Figures 1B and 1C). Interestingly, four of the six cDNAs
kb, nearly identical in size to our 5.4 kb clone. Finally,encoded proteins with one or more cyclin binding (RXL)
ectopic expression of the CP110 cDNA in mammalianmotifs (Adams et al., 1996; Chen et al., 1996; Zhu et al.,
cells yields a product that comigrates with endogenous1995; Figures 1C and 1D).
CP110 (see below).We chose to study in detail one clone encoding an
uncharacterized protein of 991 amino acids with an ap-
proximate molecular mass of 110 kDa, which we named Expression of CP110 Is Regulated
during the Cell CycleCP110 for reasons described below. This clone displayed
significant overlap with a human gene in GenBank We investigated the expression of CP110 RNA in a num-
ber of human tissues. CP110 was expressed ubiqui-(KIAA0419; GenBank accession number AB007879). We
note that this gene is highly conserved in the mouse, tously in each of the human tissues we examined, al-
though expression was significantly elevated in testisas several noncontiguous mouse ESTs with a high de-
gree of identity (at the amino acid level) to the human (Figure 3A). The importance of the latter finding remains
to be determined.gene have been sequenced (data not shown), although
convincing homologs in other eukaryotes were not ob- We also determined when CP110 was expressed dur-
ing the cell cycle by preparing quiescent human T98Gserved. CP110 does not resemble any previously char-
acterized protein, although it contains a number of rec- cells by serum deprivation and restimulating these cells
to reenter the G1 phase. Such treatment results in highlyognizable motifs, including two cyclin binding domains
(Figure 1C; Adams et al., 1996; Chen et al., 1996; Zhu synchronous progression through each stage of the cell
cycle (Figure 3B). Northern blotting of RNA preparedet al., 1995). Interestingly, one of these segments is
identical to the corresponding domain in E2F-1, a known from synchronized populations revealed that expression
of CP110 was induced at the G1-to-S transition andcyclin binding protein (Figure 1D). In addition, we identi-
fied potential “destruction” and “KEN box” degradation peaked during S phase, after which CP110 mRNA levels
decreased markedly (Figure 3B). In contrast, levels of amotifs (Glotzer et al., 1991; Pfleger and Kirschner, 2000),
as well as coiled-coil domains. CP110 has ten putative transcript encoding acidic ribosomal phosphoprotein
(ARPP0) remained unchanged throughout the cell cycle.CDK2 phosphorylation sites.
As expected, GST-tagged recombinant CP110 (GST- CP110 was expressed in each human cell line that
we tested (data not shown). To examine CP110 proteinwt) was robustly phosphorylated by cyclin E/CDK2 (Fig-
ure 2A). CP110 was also a substrate for cyclin A/CDK2 levels during cell cycle progression, we produced and
affinity purified several polyclonal antibodies againstand the mitotic kinase cyclin B/CDC2, but not the G1
phase kinase cyclin D/CDK4 (Figure 2A). In addition, amino-terminal fragments of CP110. CP110 was the pre-
dominant polypeptide visualized by Western blotting ofeach of the CDKs able to phosphorylate CP110 formed
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Figure 1. Identification of Human CP110
(A) A representative positive clone in tertiary cyclin E/CDK2 substrate screen.
(B) Sequence of CP110 with motifs (CDK binding RXL motif, coiled-coil, destruction box, KEN box, and putative CDK phosphorylation sites)
color-coded as depicted here and in (C). The “destruction box” motif overlaps with the first RXL motif.
(C) Schematic of CP110 motifs and deletions.
(D) Alignment of RXL motifs present in CP110 and other known CDK binding proteins.
crude cell lysates (Figure 3C and data not shown). Next, mitosis, including cyclin A, which is also unstable in
nocodazole-treated cells (den Elzen and Pines, 2001;we investigated CP110 protein levels in T98G cells ren-
dered quiescent and restimulated to enter the cell cycle Geley et al., 2001; Pagano et al., 1992; Pines and Hunter,
1990). Alternatively, this finding suggests, but does notas described above. CP110 was present at very low
levels in quiescent cells or early G1 phase cells reenter- prove, that CP110 protein may be stabilized by direct or
indirect interactions with microtubules emanating froming the cell cycle (Figure 3C). However, consistent with
our Northern blotting analysis, CP110 expression was centrosomes (see below). From the expression pattern
of CP110, we conclude that this protein functions some-markedly elevated as cells progressed through the G1-
to-S transition and entered S phase. CP110 levels dimin- time between the G1-to-S transition and mitosis, and
this profile is consistent with the ability of S/G2/M phaseished as cells completed mitosis and entered G1, con-
sistent with the presence of “destruction” and “KEN CDKs to phosphorylate this substrate.
box” degradation motifs, although the protein did not
disappear altogether. The results in Figure 3C therefore CP110 Is a Component of Centrosomes
We performed confocal deconvolution microscopy toshow that CP110 expression is cell cycle regulated. In
addition, we examined another human cell line (Saos2 detect the subcellular localization of CP110. Antibodies
against CP110 stained two or four prominent spots veryosteosarcoma) after synchronization by various drug
blocks. We again observed enhanced levels of CP110 close to the nucleus (Figure 4 and data not shown). As
centrosomes are positioned in close proximity to thein cells blocked at the G1-to-S phase boundary with
hydroxyurea as well as cells released from this drug into nucleus, we determined whether the CP110 polypeptide
was enriched at centrosomes by examining the stainingS phase (Figure 3D). Blocking cells in mitosis with the
microtubule-depolymerizing agent nocodazole resulted pattern of -tubulin, a well-characterized centrosomal
marker. Interestingly, CP110 staining overlapped within a marked decrease in the abundance of CP110 (Fig-
ures 3C and 3D). This observation is reminiscent of that of -tubulin, although the spots detected in each
case did not perfectly coincide with one another (Figurecertain proteins destroyed during the early stages of
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Figure 2. Substrate Specificity of Different Cyclin/CDK Complexes toward CP110
(A) CP110 is a substrate of CDK2 and CDC2. In vitro kinase assays contained wild-type CP110 (GST-wt), phosphorylation site mutant (GST-
mut) in which potential phosphorylation sites (Ser-45, Ser-170, Thr-194, Ser-366, Ser-372, Ser-400, Ser-516, and Thr-566) were replaced with
alanine, N-terminal CP110 with C-terminal RXL motif (GST-N1), N-terminal CP110 without C-terminal RXL motif (GST-N2), C-terminal RB
fragment (GST-RB), and unfused GST with purified baculovirus-expressed cyclin D1/CDK4 (D/K4), cyclin E/CDK2 (E/K2), cyclin A/CDK2 (A/K2),
or cyclin B1/CDC2 (B/C2). Reactions were resolved by SDS-PAGE and visualized by autoradiography.
(B) CP110 binds to cyclin E/CDK2, cyclin A/CDK2, and cyclin B/CDC2 in vitro. HA-tagged cyclin E/CDK2, cyclin A/CDK2, or cyclin B/CDC2
was incubated with N-terminal CP110 (GST-N1), and CP110 was detected by Western blotting after immunoprecipitation with anti-HA (12C5A)
antibody. The left-hand lane (input) represents 25% of the total CP110 in the binding reactions.
4). Identical results were obtained with multiple human fractions. We observed CP110 in fractions enriched in
centrosomes as determined by cosedimentation withcell lines (Figure 4 and data not shown).
To more precisely localize CP110 expression within -tubulin at the expected sucrose density (Figure 5B).
CP110 was the major polypeptide recognized on thesecentrosomes, we performed immunofluorescence ex-
periments with antibodies against centrin, a protein that blots. As a further control, we demonstrated that these
centrosomal fractions were devoid of potential nuclearis concentrated within the distal lumen of centrioles
(Baron et al., 1992; Paoletti et al., 1996; Stearns et al., contaminants such as cyclin D and PCNA (data not
shown). This experiment confirms that CP110 is an inte-1991). CP110 staining significantly overlapped that of
centrin, indicating that CP110 may localize to centrioles gral centrosomal component and indicates that the
centrosomal signal we observe in our immunofluores-(Figure 4, right panel). Use of a second affinity-purified
anti-CP110 antibody gave identical staining (data not cence experiments derives exclusively from CP110.
shown). To further ensure that this centrosomal staining
was due to CP110 protein and not an unexpected anti- Ablation of CP110 with siRNAs Interferes
with Centrosome Duplicationbody crossreaction, we examined the localization of
CP110 by transfecting GFP-tagged CP110, and indistin- We investigated the role of CP110 in centrosome dupli-
cation by RNA interference (RNAi)-mediated downregu-guishable results were obtained (Figure 5). These stud-
ies unequivocally pinpoint CP110 localization to centro- lation of endogenous CP110 (Elbashir et al., 2001). Small
interfering RNAs (siRNAs) corresponding to two distinctsomes (hence the name centrosomal protein of 110 kDa,
or CP110). CP110 coding sequences were chosen to target CP110,
and an irrelevant (GFP) RNA was selected as a nonspe-To confirm biochemically the localization of CP110,
we purified centrosomes through sucrose gradient cen- cific control. Transfection of either CP110 siRNA, but
not the control siRNA, resulted in a dramatic reductiontrifugation and performed Western blotting on gradient
A Centrosomal CDK2 Substrate
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Figure 3. Northern and Western Blot Analyses of CP110 Expression
(A) mRNA from different human tissues was probed with a CP110 cDNA, and -actin was used as a control after stripping the blot. PBL,
peripheral blood lymphocytes.
(B) Northern blot of mRNA isolated from T98G cells at different cell cycle stages as indicated was probed with CP110 or ARPPo cDNA as a
control (upper and middle). The cell cycle stage of each population (as a percentage) at indicated time points was determined by FACS
analysis (bottom). AS, asynchronous population.
(C) CP110 protein expression across the cell cycle. T98G cells were synchronized by serum starvation and restimulated with serum to initiate
cell cycle reentry. Cell lysates from different cell cycle stages were resolved by SDS-PAGE and blotted with affinity-purified anti-CP110
antibody. Actin was used as a loading control.
(D) Saos2 cells were synchronized with mimosine (G1), hydroxyurea (G1/S), blocked with hydroxyurea, and released for 6 hr from the hydroxyurea
(S) and nocodazole (G2/M) blocks. Cell lysates from different cell cycle stages were collected and analyzed as in (C); a loading control is
included in the bottom panel. Synchronization of populations at different cell cycle stages was determined by FACS analysis (bottom).
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Figure 4. Subcellular Localization of CP110 at Centrosomes by Indirect Immunofluorescence
Saos2 (columns 1, 2, and 3) or T98G (column 4) cells were grown on glass coverslips, fixed, and incubated with affinity-purified anti-CP110
antibody (green) and anti--tubulin antibody (red; columns 1, 2, and 3, top) or anti-centrin antibody (red; column 4, top). DNA was stained
with DAPI. Deconvolution microscopy was used to visualize the cells. Yellow color in merged images indicates colocalization of CP110 and
-tubulin or centrin. Insets show magnified view of centrosomes.
in CP110 protein levels (Figure 6A). We verified the spec- reduplication seen with the CP110 siRNAs is specific
and cannot be explained by induction of a cell cycleificity of targeting by demonstrating that -tubulin levels
were not perturbed. It has been well established that S block caused by siRNA transfection. Taken together,
we conclude that CP110 plays a critical role in promotingphase arrest leads to multiple rounds of centrosome
amplification, and this assay is widely used in centro- duplication of centrosomes.
some duplication studies (Balczon et al., 1995; Fisk and
Winey, 2001; Meraldi et al., 1999; Stucke et al., 2002). Expression of a Nonphosphorylated CP110
Mutant Induces PolyploidyS phase arrest of U2OS cells with hydroxyurea (HU)
efficiently provoked centrosome amplification as ex- To further test the role of CP110 and CDK phosphoryla-
tion in centrosome duplication, we investigated thepected (Figures 6B and 6C). Next, we tested the effect
of suppressing endogenous CP110 expression on cen- long-term effects of expressing a mutant version of
CP110 that cannot undergo CDK phosphorylation. Totrosome duplication. Centrosomes were visualized after
transfection of either CP110 siRNA (siRNA-I and siRNA- do so, we derived stable human cell lines expressing
either epitope-tagged full-length CP110 (wild-type, wt)II) or a nonspecific control (NS) using two different anti-
-tubulin (Figure 6B) or anti-centrin antibodies (data not or a mutant version of CP110 (mut) in which most of the
putative CDK phosphorylation sites were mutated toshown). Remarkably, suppression of CP110 protein by
either siRNA prevented centrosome reduplication (Fig- alanine. We derived several independent clones for each
cell line, and in each case, expression levels were com-ures 6B and 6C). In contrast, the nonspecific control
siRNA had no effect on centrosome amplification. In parable to one another and approximated the level of
endogenous CP110 protein (Figure 7A and data notlight of these results, it was important to establish that
blockage of centrosome duplication did not occur as a shown). We also derived control cell lines harboring only
the integrated expression vector. We performed kinaseconsequence of cell cycle arrest by CP110 siRNAs at a
point prior to the HU arrest. Indeed, FACS analysis and assays with the phosphorylation site mutant (GST-mut)
and demonstrated that this mutant was no longer amicroscopic inspection of transfected cells indicated
that cell cycle progression was not affected by either substrate for CDKs (Figure 2A). Importantly, centroso-
mal localization of the nonphosphorylated CP110 mu-CP110 siRNA in the presence or absence of HU (Figure
6D and data not shown). Thus, the block to centrosome tant (mut-GFP) was not affected (Figure 5A, right panel).
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Figure 5. Subcellular Localization of CP110 by GFP Fluorescence and Cosedimentation with Centrosomes on Sucrose Gradients
(A) HeLa cells were transiently transfected with GFP vector only, CP110(wt)-GFP, and CP110(mut)-GFP (green), and costained with mouse
anti--tubulin antibody (red). DNA was counterstained with DAPI (blue). Confocal laser scanning microscopy was used to visualize the cells.
Yellow color in merged images represents colocalization of CP110 and -tubulin. Inset shows magnified view of centrosomes.
(B) HeLa cell lysate was purified through a 40%–65% sucrose gradient, and the resulting fractions were separated on an SDS-PAGE gel and
Western blotted with anti-CP110 antibody, after which the blot was stripped and reprobed with anti--tubulin antibody. Input, lysate loaded
onto sucrose gradient. Fractions 2 and 3 reproducibly lacked centrosomal material.
Remarkably, expression of the CP110 phosphoryla- agreed well with our FACS experiments. These data
strongly suggest that the dominant defect provoked bytion site mutant, but not the corresponding wild-type
protein or the vector itself, induced significant poly- loss of CP110 phosphorylation is not associated with
the disruption of a particular genetic locus. Rather, weploidy (tetraploid 4N and 8N DNA content; Figure 7B).
Each of the five derivative cell lines carrying mutant conclude that disruption of CDK phosphorylation of
CP110 leads to overt polyploidy.CP110 as well as pools of such clones exhibited poly-
ploidy, although the percentage of tetraploid 4N and 8N
cells varied to some degree between different lines. To Reduction in CP110 Protein Levels or Loss
of CP110 Phosphorylation Promotesmore easily visualize the differences between the vector
control cell line and those cells stably transfected with Centrosome Separation
Next, we examined centrosome separation in the stablewild-type and mutant constructs, we arrested each cell
line at the G1-to-S transition with HU and released the CP110 wild-type and phosphoacceptor mutant cell lines
described above. Interestingly, in the CP110 mutant cellcells from this block in the presence of nocodazole.
Cells bearing the vector alone or wild-type CP110 ar- lines, we reproducibly observed (in three independent
experiments) a 3-fold increase in the number of cellsrested with a 4N DNA content indicative of a G2/M block
(Figure 7C). In contrast, cells with the phosphoacceptor with separated centrosomes relative to the stable cell
lines with wild-type CP110 (Figure 7E, left). This is signifi-site mutations arrested with an 8N DNA content. Inter-
estingly, microscopic examination of these polyploid cant in light of the fact that (1) microscopic examination
revealed that the majority of cells did not show morpho-cells did not reveal significant levels of centrosome am-
plification, nor did we observe perturbations in cell logical signs of mitosis when centrosomes are well sepa-
rated, and (2) the mutant cell line does not show overtgrowth other than polyploidy (data not shown; see
below). cell cycle deregulation; that is, by FACS analysis, the
combined fraction of cells in the S and G2/M compart-We also investigated ploidy in each of the stable cell
lines using fluorescence in situ hybridization (FISH) anal- ments is indistinguishable in mutant and wild-type lines
(data not shown).ysis. We made use of a probe hybridizing to chromo-
some 16 and confirmed that every cell line expressing We also examined centrosome separation in growing
cells depleted of CP110 by siRNA. Remarkably, we alsothe nonphosphorylated CP110 mutant, but not wild-type
CP110 or vector alone, exhibited polyploidy (Figure 7D), observed a sharp (nearly 4-fold) and reproducible (in six
independent experiments) increase in the fraction ofand the degree of polyploidy that we observed here
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Figure 6. RNAi-Mediated Suppression of CP110 Function Results in a Centrosome Duplication Defect
(A) Western blot detection of CP110 protein in U2OS cells treated with a nonspecific control siRNA (NS) or two different siRNAs corresponding
to CP110 mRNA as indicated (RNAi-I and -II). Exogenously expressed CP110 was loaded as a marker in the last lane.
(B) U2OS cells were arrested at S phase with HU treatment for 48 hr after transfection with control and two distinct CP110 siRNAs. Overduplica-
tion of centrosomes is evident in U2OS cells treated with HU (top row) but not in those cells treated with CP110 siRNA. Two independent
experiments with each of the two CP110 siRNAs are shown. Centrosomes were examined by immunofluorescence staining with two different
anti--tubulin antibodies (column 1, red; column 4, green) and affinity-purified anti-CP110 (column 2, green). Column 3 shows a merged view
of columns 1 and 2. Representative fields are shown. Insets show high-magnification views of centrosomes. Expanded views of a single
centrosome are shown in the bottom row. A second centrosome shown under lower magnification (bottom row) appears similar to the
magnified centrosome.
(C) Quantitation of results shown in (B).
(D) FACS analysis of control (NS) and CP110 siRNA-treated cells left untreated or treated with HU. Representative data are shown. Transfection
efficiency was approximately 90%.
cells with separated centrosomes when endogenous for cyclin E/CDK2 have been identified. This list includes
CP110 levels were suppressed (Figure 7E, right). Impor- the retinoblastoma tumor suppressor protein (pRB),
tantly, microscopic investigation of nuclear morphology NPAT, a regulator of S phase-specific histone transcrip-
and chromosome condensation indicated that in- tion (Ma et al., 2000; Zhao et al., 2000), PRC1, a regulator
creased levels of separation were evident in cells prior of cytokinesis (Jiang et al., 1998), and nucleophosmin
to G2 and M phase entry. Further, as described above, (NPM/B23; Okuda et al., 2000; Tokuyama et al., 2001).
depletion of CP110 in growing cells does not alter their The identification of CP110 as a physiological CDK tar-
cell cycle distribution (Figure 6D), and the proportion of get is thus an important first step in the elucidation of
cells in the S and G2/M compartments combined was critical CDK substrates that drive both the centrosome
not altered. These data strongly suggest that either and cell cycles.
depletion of CP110 protein or loss of CDK phosphoryla- Although our understanding of the controls that regu-
tion results in deregulation of controls governing centro- late the centrosome cycle—the process of duplication
some separation. and separation—is rudimentary, it is nevertheless clear
that centrosomal events are linked to the cell cycle in
general and to activation of CDKs in particular (reviewedDiscussion
in Hinchcliffe and Sluder, 2001). For example, it is clear
that activation of cyclin E/CDK2 and cyclin A/CDK2It is known that phosphorylation of critical targets by
CDKs drives the cell cycle. Yet few in vivo substrates plays a critical role in Xenopus embryos and somatic
A Centrosomal CDK2 Substrate
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Figure 7. CP110 Mutant Refractory to CDK Phosphorylation Induces Polyploidy
(A) Saos2 cells were stably transfected with wild-type (wt) HA-tagged CP110, HA-tagged CP110 mutant (mut) lacking potential CDK phosphoryla-
tion sites, or vector control. Expression of CP110 in selected stable wild-type and mutant clones (wt-c6 and wt pools, mut-c5, mut-c8, mut-
c10, and mut pools) was detected by Western blot analysis with anti-HA antibody.
(B and C) DNA content in different stable cell lines either growing asynchronously (B) or treated with HU (2 mM) for 24 hr and then released
into nocodazole (80 ng/ml) for 12 hr (C) was determined by flow cytometry (FACS) after propidium iodide staining.
(D) Fluorescence in situ hybridization (FISH) with a spectrum orange-labeled chromosome 16 satellite II probe (Vysis) was performed to
evaluate ploidy in different clones. Chromosome copy number is indicated for each stable cell line.
(E) CP110 mutant cell line and CP110 siRNA-transfected cells exhibit enhancement of unscheduled centrosome separation. Averaged data
obtained from three and six independent stable cell line and RNAi experiments, respectively, are shown.
mammalian cells, respectively, since inhibition of these target, CP110, which localizes to centrosomes. This pro-
tein does not resemble any previously characterizedenzymes can prevent centrosome duplication (Hinch-
cliffe et al., 1999; Lacey et al., 1999; Meraldi et al., 1999). protein. Intriguingly, this protein has a cyclin binding
domain (also known as RXL or Cy motif) that is nearlyGiven the temporal connections between the centro-
some cycle and CDK activation, a reasonable assump- identical to that of E2F-1 which confers stable binding
to cyclin/CDK complexes. Expression of the CP110 genetion is that centrosomal CDK targets are likely to exist.
Indeed, this appears to be the case. One substrate of is induced at the G1-to-S transition, and its levels peak
around S phase, diminishing in mitosis. Thus, the ap-cyclin E/CDK2, nucleophosmin (NPM/B23), has been
implicated in the regulation of centrosome duplication pearance of CP110 coincides with the activation of
CDK2 and key events in the initiation of centrosome(Okuda et al., 2000; Tokuyama et al., 2001). In this work,
microinjection of anti-NPM/B23 antibodies or removal duplication. Most importantly, we have directly shown
that CP110 plays a role in the regulation of centrosomeof NPM/B23 phosphorylation sites resulted in a block
to centrosome duplication, suggesting that CDKs posi- reproduction, since RNAi-mediated suppression of en-
dogenous CP110 prevents centrosome reduplication intively regulate initiation of this event. More recently, a
mouse CDK substrate, mMps1, has been characterized. S phase-arrested cells. These observations are consis-
tent with a positive role for CP110 in promoting theMps1 is a kinase involved in centrosome duplication,
and its stability is promoted by CDK2 activity (Fisk and centrosome cycle.
Suppression of CP110 dramatically affects centro-Winey, 2001). Interestingly, Xenopus Mps1 also appears
to associate with kinetochores and plays a role in the some reproduction in cells arrested at S phase. Under
normal, unperturbed conditions, RNAi suppression ofmitotic spindle checkpoint (Abrieu et al., 2001).
In this report, we describe the isolation of a CDK CP110 interferes with centrosome separation, yet we
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noticed that a fraction of cells treated with CP110 siR- are under way to elucidate the molecular mechanisms
NAs have two centrosomes. Our interpretation is as fol- through which CP110 functions. We found that either
lows. CP110 is an integral centrosome component downregulation of CP110 in growing cells through RNAi
whose levels may be one of the limiting factors for cen- or loss of CDK phosphorylation results in unscheduled
trosome duplication. This is consistent with the observa- centrosome separation. These data, in combination with
tion that it is induced at the G1-to-S transition at a time our RNAi experiments in S phase-arrested cells, lead to
when centrosomes begin to duplicate, and its levels the intriguing hypothesis that CP110 might function in
sharply decrease in mitosis prior to the next cell cycle/ two ways, first to positively regulate centrosome dupli-
duplication event. However, even under ideal condi- cation, and second to suppress premature centrosome
tions, we can only eliminate 90% of CP110 using RNAi, separation. In normal cells, centrosome separation oc-
as judged by immunofluorescence. If CP110 is function- curs during the G2-to-M transition and is linked to a
ing catalytically or even structurally, there may be prior, obligatory (S phase) duplication event. One inter-
enough residual protein after RNAi to allow for a single esting possibility is that CP110 functions as a sensor
duplication event but not multiple ones. This could also that couples the two events. Defects in such a sensor
explain the absence of a cell cycle block during the could give rise to genomic instability.
transient RNAi treatment of cycling cells. However, S Alternatively, CP110 might play a structural role in the
phase arrest normally results in centrosome amplifica- assembly of centrosomes or centrioles, or it might play
tion due to multiple duplication or reproduction events. a role in the maintenance of centrosome adherence. If
Thus, if CP110 is limiting as a result of RNAi, centro- so, the aberrant splitting of centrosomes that we ob-
somes will be unable to undergo multiple duplication serve could result from a loss of structural integrity when
events, and amplification will not occur. This will there- CP110 is mutated or depleted.
fore reveal a centrosome reproduction (or duplication) Recent experiments suggest that the Cdc14A phos-
defect. Absolute proof that CP110 plays a role in duplica- phatase localizes to centrosomes, and overexpression
tion under normal conditions will require the complete of this enzyme provokes premature centrosome separa-
removal of this protein using a (most likely conditional) tion (Mailand et al., 2002). This observation is reminis-
gene knockout strategy. cent of our findings with the stable CP110 phosphoac-
We have also demonstrated that loss of CP110 phos- ceptor mutant cells, suggesting that CP110 might be a
phorylation in human cells leads to significant poly- substrate for this phosphatase. Future experiments will
ploidy, characterized by large populations of tetraploid determine whether Cdc14A and CP110 are engaged in
4N and 8N cells. Because CP110 appears to be concen- a single pathway in which the balance of phosphoryla-
trated at centrosomes, the defect caused by loss of tion of this CDK substrate regulates the proper timing
CP110 phosphorylation appears to be due to an intrin- of events in the centrosome cycle.
sic, dominant loss of centrosome function. It is interest-
ing to note that we do not observe a high fraction of Experimental Procedures
CP110 mutant cells with 8N or greater DNA content.
Expression and Purification of Cyclin/CDK ComplexesInstead, once a certain DNA content was attained, it
and Kinase Assaysremained constant (data not shown). Nor did we observe
Infection of insect cells with recombinant baculoviruses, purificationcentrosomal hyperamplification in these stable, mutant
of cyclin D1/CDK4, cyclin E/CDK2, cyclin A/CDK2, and cyclin
cell lines. It is possible that these cells have reached a B/CDC2 kinase complexes, and kinase assay conditions have been
steady-state DNA content and that cells with higher described (Dynlacht et al., 1994). Kinase assays were performed
ploidy were nonviable. Indeed, evidence for a “genomic with 0.5–1g of GST, GST-RB C-terminal fragment, GST-CP110(wt),
GST-CP110(mut), GST-CP110N1, or GST-CP110N2, and 50 ngconvergence” model has been obtained, wherein it has
of each kinase.been shown that heterogeneity in chromosome number
and centrosome amplification was suppressed over
Preparation of Labeled Cyclin E/CDK Probe and Phagetime in cultured p53/ cells (Chiba et al., 2000).
Expression Library ScreeningOur results can be explained in light of the essential
A mixture of purified wild-type and dominant-negative cyclin
role that centrosomes play in chromosome segregation E/CDK2 labeled with [ 32P]ATP was used as a probe to screen a
and cytokinesis. Such a model makes the prediction that GEX5-HS HeLa cDNA expression library (Fukunaga and Hunter,
mutations might exist in proteins normally regulating 1997), essentially as previously described (Zhao et al., 1998). Posi-
tive clones were identified and verified by secondary and tertiarycentrosome duplication and that such mutations could
screening. A screen of 2  105 phage plaques yielded six positivegive rise to genetic instability and cancer. Interestingly,
clones. A partial CP110 cDNA fragment (nucleotides 637–2517 rela-the CP110 gene maps to chromosomal locus 16p12-
tive to the full-length clone) was isolated from this screen, andp13, and abnormalities of this region have been linked
database searches revealed the existence of a longer clone
to familial and nonfamilial neuroblastoma and other can- (KIAA0419) that we obtained from Kazusa DNA Research Institute
cers (Weiss et al., 2000). Experiments are underway to (Chiba, Japan).
determine more precisely whether the CP110 gene is
a target of mutations in human cancers. As abnormal Molecular Cloning and Site-Directed Mutagenesis
To generate GST-CP110, GST-CP110N1, and GST-CP110N2 fu-chromosome segregation and genetic instability are
sion proteins, the sequences of CP110 encoding residues 1–991,common hallmarks of a cancer cell, it will be important
1–629, and 1–529, respectively, were amplified by PCR using Pfuto understand the role of CP110 in the centrosome cycle
turbo polymerase (Stratagene) and subcloned into the BamHI and
and to determine its role, if any, in the etiology of human NotI of pGEX-4T-1 vector. To generate mutants, potential phosphor-
cancer. ylation sites (Ser-45, Ser-170, Thr-194, Ser-366, Ser-372, Ser-400,
It is not yet known whether CP110 plays a regulatory Ser-516, and Thr-566) in CP110 were replaced with alanine using
Quick Change mutagenesis (Stratagene). The HA-tagged CP110(wt)or structural role at the centrosome, and experiments
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and CP110(mut) expression constructs were made by cloning the CTT-3 (RNAi-I) and 5-AUG UUC UUC UCC AAG GUG CTT-3 (RNAi-
II), respectively. The synthetic oligonucleotides were from Dhar-full-length CP110 and the phosphorylation site mutant cDNAs into
the BamHI and NotI of pcDEF3-HA vector. Flag-tagged CP110 was macon Research. Transfection of siRNAs for targeting endogenous
CP110 was carried out using Oligofectamine (Invitrogen) accordingmade by PCR amplification of the full-length CP110 cDNA sequence
and insertion into the SalI and BamHI sites of pFLAG-CMV2 vector. to the manufacturer’s protocol.
The GFP-tagged CP110(wt) and CP110(mut) expression constructs
were made by cloning into the XhoI and BamHI sites of pEGFP-N1 Selection of Stable Cell Lines
vector (Clontech). All constructs were verified by DNA sequencing. Saos2 cells were transfected with pcDEF3-HA vector, pcDEF3-HA-
CP110(wt), and pcDEF3-HA-CP110(mut) using calcium phosphate.
Antibodies After 48 hr, the cells were split and treated with G418 for 1 month.
To generate anti-CP110 antibodies, a GST fusion protein encoding Stable transfectants were cloned and confirmed by Western blot
residues 1–149 was produced in bacteria. GST was removed from assay.
the fusion protein using Prescission protease (Amersham Phar-
macia) and was used to immunize rabbits after coupling to keyhole Fluorescence In Situ Hybridization
limpet hemocyanin (KLH). Polyclonal antibodies against CP110 were For fluorescence in situ hybridization (FISH) analysis, a spectrum
purified using a GST-CP110 fusion protein affinity column. orange-labeled chromosome 16 satellite II probe (Vysis) was used
according to the manufacturer’s protocol. Slides were washed,
Cell Cycle Synchronization, FACS Analysis, and Northern counterstained with DAPI, and chromosome copy number/cell tabu-
and Western Blotting lated.
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